Author pages are created from data sourced from our academic publisher partnerships and public sources.
MDM4 is a key therapeutic target in cutaneous melanoma
The inactivation of the p53 tumor suppressor pathway, which often occurs through mutations in TP53 (encoding tumor protein 53) is a common step in human cancer. However, in melanoma—a highly… Expand
Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment.
- F. Lamoureux, G. Moriceau, G. Picarda, J. Rousseau, V. Trichet, F. Rédiní
- Medicine, Biology
- Biochimica et biophysica acta
Tumor development in bone is often associated with fractures, bone loss and bone pain, and improvement is still needed in therapeutic approaches. Bone tumors are related to the existence of a vicious… Expand
Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models
Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone. A lack of response to chemotherapeutic treatments shows the… Expand
Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth
Osteosarcoma is the most frequent malignant primary bone tumor that occurs mainly in the young, with an incidence peak observed at age 18 years. Both apomine and lovastatin have antitumor activity in… Expand
Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.
Despite recent improvements in therapeutic management of osteosarcoma, ongoing challenges in improving the response to chemotherapy warrants new strategies still needed to improve overall patient… Expand
Therapeutic approach of primary bone tumours by bisphosphonates.
Bone tumours can be dissociated in two main categories: i) primary bone tumours (benign or malignant) including mainly osteosarcoma and other sarcomas.ii)and giant cell tumour and bone metastases… Expand
mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours.
N-BP, rapamycin and its derivatives have been originally developed respectively as anti-resorptive and anti-fungal agents. In fact, in vitro and in vivo experiments demonstrated that these compounds… Expand
Pharmacological blocking of the osteoclastic biocorrosion of surgical stainless steel in vitro.
- S. Lionetto, A. Little, +5 authors D. Cadosch
- Materials Science, Medicine
- Journal of biomedical materials research. Part A
- 1 April 2013
In vitro studies suggest that human osteoclasts (OC) are able to corrode surgical stainless steel 316L (SS). The aim of this study was to investigate whether osteoclastic biocorrosion can be blocked… Expand
Synergistic inhibition of osteosarcoma cell growth by combination of RAD001 (everolimus) and zoledronic acid
Osteosarcoma is the most frequent malignant primary bone tumors. Despite recent improvements in multimodal therapy the problem of non-response to mono-chemotherapy remains. Therefore, novel… Expand
Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells